Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice.
Document Type
Article
Publication Date
1-1-2025
Abstract
BACKGROUND: Satralizumab is approved for aquaporin-4 immunoglobulin G-positive (AQP4-IgG
METHODS: Case information for patients with AQP4-IgG
RESULTS: Of 43 patients, 88% were female and 44% self-identified as Black. Median age was 54 (range, 20-82) years, and time since confirmed NMOSD diagnosis was 8 (1-18) years. Reasons for satralizumab initiation included intolerance/safety concerns with existing therapy (30%), new diagnosis (26%), and inadequate disease control (21%). The median duration of satralizumab treatment was 31 (range, 7-104) months, during which three patients (7%) had radiographically confirmed relapses and 15 (35%) experienced a related adverse event. At data cutoff, 35 patients (81%) were receiving satralizumab.
CONCLUSION: Satralizumab was effective and well tolerated in patients with NMOSD, including those who switched from previous treatments due to inadequate disease control and/or intolerance. These real-world outcomes align with long-term safety and efficacy findings from the Phase III SAkura trials.
Publication Title
Mult Scler J Exp Transl Clin
Volume
11
Issue
4
First Page
20552173251386895
Last Page
20552173251386895
Recommended Citation
Abboud, H., Steingo, B., Vargas, D., Patel, J., Willis, M., Mao-Draayer, Y., Khaitov, D., Avila Ornelas, J., Subei, A., Reed, C., Baek, W., Tsai, M., Kim, A., Obeidat, A., Pandey, K., Levy, M., Molazadeh, N., Shin, R., Romero, R., Goulette, P., Walch, R., Coté, J., Pace, R., Sengul, B., Osborne, B., Mahadeen, A., Ferayorni, L., & Gholizadeh, S. (2025). Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice.. Mult Scler J Exp Transl Clin, 11 (4), 20552173251386895-20552173251386895. https://doi.org/https://doi.org/10.1177/20552173251386895